| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 90 | 2022 | 1201 | 5.780 |
Why?
|
| Immunosuppressive Agents | 29 | 2021 | 995 | 1.380 |
Why?
|
| Islets of Langerhans Transplantation | 12 | 2021 | 247 | 1.350 |
Why?
|
| Living Donors | 14 | 2022 | 348 | 1.340 |
Why?
|
| Graft Rejection | 39 | 2014 | 1126 | 1.250 |
Why?
|
| Hepatectomy | 12 | 2011 | 178 | 1.230 |
Why?
|
| Liver Diseases | 11 | 2014 | 249 | 1.160 |
Why?
|
| Tacrolimus | 19 | 2014 | 373 | 1.100 |
Why?
|
| Portal Vein | 7 | 2018 | 122 | 0.990 |
Why?
|
| Graft Survival | 31 | 2018 | 942 | 0.920 |
Why?
|
| Tissue Donors | 12 | 2016 | 542 | 0.860 |
Why?
|
| Liver Neoplasms | 12 | 2010 | 793 | 0.830 |
Why?
|
| Kidney Transplantation | 24 | 2012 | 882 | 0.800 |
Why?
|
| Postoperative Complications | 22 | 2022 | 2591 | 0.780 |
Why?
|
| Surgical Mesh | 4 | 2007 | 125 | 0.750 |
Why?
|
| Tissue and Organ Procurement | 10 | 2022 | 388 | 0.740 |
Why?
|
| Pancreas Transplantation | 10 | 2006 | 105 | 0.740 |
Why?
|
| Hepatic Artery | 7 | 2006 | 84 | 0.690 |
Why?
|
| Organ Transplantation | 5 | 2017 | 298 | 0.690 |
Why?
|
| Humans | 160 | 2022 | 96112 | 0.650 |
Why?
|
| Islets of Langerhans | 6 | 2018 | 559 | 0.600 |
Why?
|
| Liver, Artificial | 4 | 2002 | 7 | 0.580 |
Why?
|
| Liver Failure | 4 | 2004 | 69 | 0.570 |
Why?
|
| Quality Improvement | 1 | 2022 | 502 | 0.560 |
Why?
|
| Abdominal Cavity | 2 | 2007 | 17 | 0.530 |
Why?
|
| Adult | 75 | 2021 | 28725 | 0.510 |
Why?
|
| Hernia, Inguinal | 2 | 2006 | 75 | 0.440 |
Why?
|
| End Stage Liver Disease | 1 | 2015 | 73 | 0.430 |
Why?
|
| Child | 42 | 2022 | 7625 | 0.420 |
Why?
|
| Muromonab-CD3 | 11 | 1998 | 70 | 0.390 |
Why?
|
| Liver | 11 | 2022 | 1238 | 0.390 |
Why?
|
| Follow-Up Studies | 26 | 2018 | 3927 | 0.380 |
Why?
|
| Insulin-Secreting Cells | 4 | 2019 | 442 | 0.380 |
Why?
|
| Cyclosporine | 10 | 1998 | 242 | 0.380 |
Why?
|
| Wounds, Gunshot | 2 | 2021 | 121 | 0.380 |
Why?
|
| Sirolimus | 1 | 2014 | 177 | 0.380 |
Why?
|
| Hepatocytes | 3 | 2002 | 132 | 0.370 |
Why?
|
| Polyethylene Glycols | 2 | 2014 | 376 | 0.360 |
Why?
|
| Male | 74 | 2021 | 45871 | 0.360 |
Why?
|
| Female | 67 | 2022 | 50045 | 0.350 |
Why?
|
| Intestines | 1 | 2014 | 431 | 0.350 |
Why?
|
| Prostheses and Implants | 2 | 2010 | 132 | 0.350 |
Why?
|
| Diabetes Mellitus, Type 1 | 5 | 2021 | 595 | 0.330 |
Why?
|
| Veterans | 1 | 2011 | 100 | 0.330 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 2014 | 350 | 0.310 |
Why?
|
| Obesity | 2 | 2019 | 1034 | 0.310 |
Why?
|
| Stents | 4 | 2021 | 425 | 0.310 |
Why?
|
| Duodenum | 3 | 2006 | 112 | 0.300 |
Why?
|
| Child, Preschool | 26 | 2016 | 3974 | 0.290 |
Why?
|
| Time Factors | 28 | 2015 | 5585 | 0.290 |
Why?
|
| Lysine | 1 | 2010 | 190 | 0.290 |
Why?
|
| Jaundice, Obstructive | 1 | 2008 | 11 | 0.290 |
Why?
|
| Carcinoma, Hepatocellular | 6 | 2010 | 426 | 0.280 |
Why?
|
| Middle Aged | 47 | 2021 | 28371 | 0.280 |
Why?
|
| Jejunum | 2 | 2006 | 80 | 0.280 |
Why?
|
| Crohn Disease | 2 | 2014 | 806 | 0.280 |
Why?
|
| Liver Abscess | 1 | 2007 | 10 | 0.270 |
Why?
|
| Fasting | 2 | 2018 | 164 | 0.270 |
Why?
|
| Hemangioma, Cavernous | 1 | 2008 | 69 | 0.270 |
Why?
|
| Dimethylpolysiloxanes | 1 | 2007 | 12 | 0.270 |
Why?
|
| Silicones | 1 | 2007 | 21 | 0.270 |
Why?
|
| Kidney | 5 | 2007 | 1156 | 0.270 |
Why?
|
| Health Care Reform | 1 | 2008 | 86 | 0.270 |
Why?
|
| Pyelonephritis, Xanthogranulomatous | 1 | 2007 | 3 | 0.260 |
Why?
|
| Minocycline | 1 | 2007 | 15 | 0.260 |
Why?
|
| Treatment Outcome | 20 | 2015 | 9176 | 0.260 |
Why?
|
| Duodenal Diseases | 1 | 2007 | 25 | 0.260 |
Why?
|
| Patient Selection | 3 | 2020 | 709 | 0.260 |
Why?
|
| Liver Failure, Acute | 1 | 2007 | 39 | 0.260 |
Why?
|
| Diverticulum | 1 | 2007 | 45 | 0.250 |
Why?
|
| Infant | 21 | 2015 | 3363 | 0.250 |
Why?
|
| Rectal Diseases | 1 | 2006 | 23 | 0.250 |
Why?
|
| Bacterial Infections | 2 | 2005 | 185 | 0.250 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 4 | 2005 | 43 | 0.250 |
Why?
|
| Anti-Bacterial Agents | 3 | 2007 | 847 | 0.240 |
Why?
|
| Colonic Diseases | 1 | 2006 | 61 | 0.240 |
Why?
|
| Adolescent | 30 | 2021 | 9895 | 0.240 |
Why?
|
| Tendons | 1 | 2006 | 49 | 0.240 |
Why?
|
| Antiviral Agents | 3 | 2022 | 504 | 0.240 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 1 | 2005 | 9 | 0.240 |
Why?
|
| Foreign Bodies | 1 | 2006 | 66 | 0.240 |
Why?
|
| Hepatic Veins | 2 | 2002 | 26 | 0.230 |
Why?
|
| Bioprosthesis | 1 | 2005 | 43 | 0.230 |
Why?
|
| Ileostomy | 1 | 2005 | 29 | 0.230 |
Why?
|
| Anesthesia, Local | 1 | 2005 | 28 | 0.230 |
Why?
|
| Prosthesis-Related Infections | 1 | 2005 | 60 | 0.230 |
Why?
|
| Retrospective Studies | 30 | 2016 | 10287 | 0.220 |
Why?
|
| Graft Occlusion, Vascular | 3 | 2002 | 100 | 0.220 |
Why?
|
| Transplantation, Homologous | 17 | 2013 | 1023 | 0.220 |
Why?
|
| Prosthesis Implantation | 1 | 2005 | 131 | 0.210 |
Why?
|
| Catheterization | 1 | 2005 | 238 | 0.210 |
Why?
|
| Cyclic GMP | 1 | 2004 | 62 | 0.210 |
Why?
|
| Pancreatitis, Chronic | 2 | 2015 | 61 | 0.210 |
Why?
|
| Survival Rate | 15 | 2014 | 1985 | 0.200 |
Why?
|
| Pancreas | 4 | 2018 | 264 | 0.200 |
Why?
|
| Morbidity | 2 | 2022 | 160 | 0.200 |
Why?
|
| Prospective Studies | 12 | 2021 | 4672 | 0.200 |
Why?
|
| Bile Ducts | 2 | 2002 | 61 | 0.200 |
Why?
|
| Ultrasonography, Doppler | 2 | 2002 | 83 | 0.190 |
Why?
|
| Extracorporeal Circulation | 1 | 2002 | 37 | 0.190 |
Why?
|
| Blood Loss, Surgical | 2 | 2001 | 133 | 0.190 |
Why?
|
| Cholecystectomy | 1 | 2002 | 26 | 0.190 |
Why?
|
| China | 4 | 2015 | 264 | 0.190 |
Why?
|
| Thrombosis | 4 | 2002 | 326 | 0.180 |
Why?
|
| Cannabidiol | 1 | 2022 | 9 | 0.180 |
Why?
|
| Pancreatectomy | 3 | 2018 | 168 | 0.180 |
Why?
|
| Rectus Abdominis | 2 | 2013 | 41 | 0.180 |
Why?
|
| Abdominal Wall | 2 | 2013 | 32 | 0.180 |
Why?
|
| Hepatitis C | 4 | 2012 | 185 | 0.180 |
Why?
|
| Mortality | 1 | 2022 | 154 | 0.180 |
Why?
|
| Head Injuries, Penetrating | 1 | 2022 | 67 | 0.170 |
Why?
|
| Monitoring, Physiologic | 1 | 2002 | 273 | 0.170 |
Why?
|
| Vascularized Composite Allotransplantation | 1 | 2021 | 17 | 0.170 |
Why?
|
| Intraoperative Complications | 1 | 2002 | 197 | 0.170 |
Why?
|
| Hypertension, Portal | 3 | 1998 | 47 | 0.170 |
Why?
|
| Prognosis | 8 | 2018 | 4029 | 0.160 |
Why?
|
| Vena Cava, Inferior | 1 | 2021 | 143 | 0.160 |
Why?
|
| Perfusion | 2 | 2022 | 266 | 0.160 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2022 | 125 | 0.160 |
Why?
|
| Policy | 1 | 2020 | 42 | 0.160 |
Why?
|
| Host-Pathogen Interactions | 1 | 2022 | 241 | 0.160 |
Why?
|
| Biliary Tract Diseases | 2 | 1997 | 37 | 0.160 |
Why?
|
| Prisoners | 2 | 2011 | 48 | 0.150 |
Why?
|
| Bile Duct Neoplasms | 2 | 2018 | 91 | 0.150 |
Why?
|
| Waiting Lists | 4 | 2007 | 212 | 0.150 |
Why?
|
| Hepatitis B | 5 | 2010 | 82 | 0.150 |
Why?
|
| Thrombectomy | 1 | 2021 | 220 | 0.150 |
Why?
|
| Laparoscopy | 1 | 2005 | 784 | 0.140 |
Why?
|
| Reperfusion Injury | 2 | 1997 | 148 | 0.140 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2012 | 488 | 0.140 |
Why?
|
| Informed Consent | 3 | 2011 | 281 | 0.140 |
Why?
|
| Venous Thrombosis | 1 | 2021 | 257 | 0.140 |
Why?
|
| Absorptiometry, Photon | 1 | 2019 | 110 | 0.140 |
Why?
|
| Biological Products | 1 | 2021 | 179 | 0.140 |
Why?
|
| Health Policy | 2 | 2011 | 208 | 0.140 |
Why?
|
| Immunity, Innate | 1 | 2022 | 464 | 0.140 |
Why?
|
| Anastomosis, Surgical | 4 | 2006 | 283 | 0.140 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 1998 | 11 | 0.140 |
Why?
|
| Kidney Failure, Chronic | 3 | 2010 | 432 | 0.140 |
Why?
|
| Reoperation | 15 | 1999 | 707 | 0.140 |
Why?
|
| Urea | 1 | 1998 | 60 | 0.140 |
Why?
|
| Ammonia | 1 | 1998 | 45 | 0.140 |
Why?
|
| Donor Selection | 2 | 2018 | 81 | 0.140 |
Why?
|
| Cultural Characteristics | 2 | 2015 | 19 | 0.140 |
Why?
|
| HIV Infections | 3 | 2012 | 974 | 0.140 |
Why?
|
| Body Mass Index | 2 | 2019 | 815 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2008 | 2781 | 0.130 |
Why?
|
| Gallbladder | 1 | 1997 | 33 | 0.130 |
Why?
|
| Occlusive Dressings | 1 | 1996 | 7 | 0.130 |
Why?
|
| Chicago | 5 | 2021 | 1506 | 0.130 |
Why?
|
| Laparotomy | 2 | 2007 | 69 | 0.130 |
Why?
|
| Polytetrafluoroethylene | 1 | 1996 | 74 | 0.130 |
Why?
|
| Cyclosporins | 6 | 1991 | 56 | 0.120 |
Why?
|
| Liver Cirrhosis | 4 | 2010 | 276 | 0.120 |
Why?
|
| Biliary Atresia | 4 | 1995 | 24 | 0.120 |
Why?
|
| Cholangiocarcinoma | 3 | 2010 | 80 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 5 | 2004 | 1429 | 0.120 |
Why?
|
| Stomach | 2 | 2006 | 115 | 0.120 |
Why?
|
| Tissue Preservation | 1 | 2015 | 15 | 0.110 |
Why?
|
| Gift Giving | 1 | 2015 | 5 | 0.110 |
Why?
|
| Social Control, Formal | 1 | 2015 | 12 | 0.110 |
Why?
|
| Volition | 1 | 2015 | 18 | 0.110 |
Why?
|
| Steroids | 1 | 1996 | 174 | 0.110 |
Why?
|
| Pentanoic Acids | 1 | 2014 | 6 | 0.110 |
Why?
|
| Cholangitis, Sclerosing | 2 | 2013 | 54 | 0.110 |
Why?
|
| Biotin | 1 | 2014 | 46 | 0.110 |
Why?
|
| Universities | 1 | 2015 | 154 | 0.110 |
Why?
|
| International Agencies | 1 | 2014 | 34 | 0.110 |
Why?
|
| Surface-Active Agents | 1 | 2014 | 62 | 0.110 |
Why?
|
| Mixed Tumor, Malignant | 1 | 1994 | 4 | 0.110 |
Why?
|
| United States | 8 | 2021 | 7768 | 0.100 |
Why?
|
| Body Height | 1 | 2014 | 108 | 0.100 |
Why?
|
| Mycophenolic Acid | 3 | 1998 | 86 | 0.100 |
Why?
|
| Colectomy | 3 | 2007 | 192 | 0.100 |
Why?
|
| Carcinosarcoma | 1 | 1994 | 29 | 0.100 |
Why?
|
| Transplantation Immunology | 1 | 2014 | 83 | 0.100 |
Why?
|
| Health Behavior | 1 | 2015 | 191 | 0.100 |
Why?
|
| Surgical Flaps | 2 | 2013 | 259 | 0.100 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2007 | 83 | 0.100 |
Why?
|
| Morphogenesis | 1 | 2014 | 211 | 0.100 |
Why?
|
| Aged | 14 | 2016 | 20972 | 0.100 |
Why?
|
| Cadaver | 4 | 2002 | 204 | 0.100 |
Why?
|
| Cryopreservation | 1 | 2013 | 72 | 0.100 |
Why?
|
| Liver Function Tests | 3 | 1997 | 94 | 0.090 |
Why?
|
| Heart Transplantation | 6 | 2008 | 812 | 0.090 |
Why?
|
| Monitoring, Immunologic | 1 | 2012 | 19 | 0.090 |
Why?
|
| International Cooperation | 2 | 2011 | 134 | 0.090 |
Why?
|
| Opportunistic Infections | 2 | 2010 | 60 | 0.090 |
Why?
|
| Capital Punishment | 1 | 2011 | 3 | 0.090 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 2 | 1989 | 97 | 0.090 |
Why?
|
| Models, Theoretical | 1 | 2014 | 503 | 0.090 |
Why?
|
| Rats, Inbred Lew | 3 | 2010 | 214 | 0.090 |
Why?
|
| Coinfection | 1 | 2012 | 67 | 0.090 |
Why?
|
| Animals | 13 | 2022 | 28919 | 0.090 |
Why?
|
| Hepatoblastoma | 2 | 2010 | 15 | 0.090 |
Why?
|
| Immunologic Factors | 1 | 2013 | 179 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2013 | 358 | 0.090 |
Why?
|
| Hepatitis C, Chronic | 1 | 2012 | 96 | 0.090 |
Why?
|
| Liver Regeneration | 1 | 2011 | 36 | 0.090 |
Why?
|
| Tumor Virus Infections | 2 | 2005 | 83 | 0.090 |
Why?
|
| Platelet Count | 1 | 2011 | 97 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 2 | 1994 | 725 | 0.080 |
Why?
|
| Survival Analysis | 8 | 2012 | 1546 | 0.080 |
Why?
|
| Death | 1 | 2011 | 97 | 0.080 |
Why?
|
| Fascia | 1 | 2010 | 32 | 0.080 |
Why?
|
| Hepatic Encephalopathy | 2 | 2001 | 38 | 0.080 |
Why?
|
| Hyperoxaluria | 1 | 2010 | 26 | 0.080 |
Why?
|
| Hemangioendothelioma | 1 | 2010 | 9 | 0.080 |
Why?
|
| Incidence | 6 | 2012 | 1715 | 0.080 |
Why?
|
| Capsules | 1 | 2010 | 38 | 0.080 |
Why?
|
| Alginates | 1 | 2010 | 17 | 0.080 |
Why?
|
| Polylysine | 1 | 2010 | 34 | 0.080 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 2061 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 1991 | 713 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 569 | 0.080 |
Why?
|
| Antibodies | 4 | 2000 | 356 | 0.080 |
Why?
|
| Costs and Cost Analysis | 3 | 2021 | 157 | 0.080 |
Why?
|
| Transplantation Tolerance | 1 | 2011 | 143 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 1973 | 0.080 |
Why?
|
| Enterococcus | 2 | 2001 | 35 | 0.080 |
Why?
|
| Radiography | 3 | 2007 | 826 | 0.080 |
Why?
|
| Interferon-gamma | 1 | 2011 | 467 | 0.080 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 1989 | 432 | 0.080 |
Why?
|
| Young Adult | 6 | 2019 | 7025 | 0.080 |
Why?
|
| Resuscitation | 2 | 2022 | 131 | 0.080 |
Why?
|
| ABO Blood-Group System | 2 | 2008 | 60 | 0.080 |
Why?
|
| Age Factors | 5 | 2019 | 1963 | 0.070 |
Why?
|
| Drug Compounding | 1 | 2010 | 88 | 0.070 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 2040 | 0.070 |
Why?
|
| Sarcoma | 1 | 2010 | 225 | 0.070 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2008 | 32 | 0.070 |
Why?
|
| Neuroendocrine Tumors | 1 | 2010 | 136 | 0.070 |
Why?
|
| Documentation | 1 | 2009 | 103 | 0.070 |
Why?
|
| Illinois | 2 | 2002 | 531 | 0.070 |
Why?
|
| Amikacin | 1 | 2007 | 5 | 0.070 |
Why?
|
| C-Peptide | 2 | 2018 | 186 | 0.070 |
Why?
|
| Blood Group Incompatibility | 1 | 2008 | 22 | 0.070 |
Why?
|
| Guanine | 1 | 2008 | 207 | 0.070 |
Why?
|
| Ciprofloxacin | 1 | 2007 | 25 | 0.070 |
Why?
|
| Kidney Diseases | 3 | 2005 | 325 | 0.070 |
Why?
|
| Rats | 6 | 2010 | 4155 | 0.070 |
Why?
|
| Organ Preservation | 3 | 2022 | 130 | 0.070 |
Why?
|
| Lymphoproliferative Disorders | 3 | 2001 | 109 | 0.070 |
Why?
|
| Body Weight | 2 | 2014 | 460 | 0.070 |
Why?
|
| Biopsy | 5 | 1999 | 1220 | 0.070 |
Why?
|
| Pseudomonas Infections | 1 | 2007 | 95 | 0.060 |
Why?
|
| Iliac Vein | 1 | 2007 | 32 | 0.060 |
Why?
|
| Health Care Rationing | 2 | 2004 | 85 | 0.060 |
Why?
|
| Creatinine | 5 | 1999 | 299 | 0.060 |
Why?
|
| Prednisone | 5 | 1998 | 258 | 0.060 |
Why?
|
| Acne Vulgaris | 1 | 2007 | 36 | 0.060 |
Why?
|
| Iliac Artery | 1 | 2007 | 42 | 0.060 |
Why?
|
| Splenic Artery | 1 | 2006 | 10 | 0.060 |
Why?
|
| Rare Diseases | 1 | 2007 | 71 | 0.060 |
Why?
|
| Aorta, Abdominal | 1 | 2006 | 60 | 0.060 |
Why?
|
| Medical Oncology | 1 | 2010 | 408 | 0.060 |
Why?
|
| Pressure | 1 | 2007 | 175 | 0.060 |
Why?
|
| Intestinal Perforation | 1 | 2006 | 39 | 0.060 |
Why?
|
| Ethics, Medical | 1 | 2009 | 312 | 0.060 |
Why?
|
| Length of Stay | 3 | 2001 | 833 | 0.060 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 1094 | 0.060 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2007 | 202 | 0.060 |
Why?
|
| Polypropylenes | 1 | 2005 | 23 | 0.060 |
Why?
|
| Anal Canal | 1 | 2006 | 92 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2019 | 2480 | 0.060 |
Why?
|
| Necrosis | 1 | 2006 | 210 | 0.060 |
Why?
|
| Transplantation, Autologous | 2 | 2018 | 362 | 0.060 |
Why?
|
| Blood Glucose | 3 | 2018 | 873 | 0.060 |
Why?
|
| Biopsy, Needle | 3 | 1998 | 232 | 0.060 |
Why?
|
| Chronic Disease | 4 | 2008 | 983 | 0.060 |
Why?
|
| Drug Resistance | 2 | 1996 | 237 | 0.060 |
Why?
|
| Risk Factors | 10 | 2012 | 5961 | 0.060 |
Why?
|
| Anesthesia, General | 1 | 2006 | 127 | 0.060 |
Why?
|
| BK Virus | 1 | 2005 | 24 | 0.060 |
Why?
|
| Polyomavirus Infections | 1 | 2005 | 29 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 1230 | 0.060 |
Why?
|
| Isoxazoles | 1 | 2005 | 78 | 0.060 |
Why?
|
| Nephrectomy | 1 | 2007 | 297 | 0.050 |
Why?
|
| Acute Disease | 4 | 1999 | 872 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2005 | 220 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2018 | 3110 | 0.050 |
Why?
|
| Biocompatible Materials | 1 | 2005 | 201 | 0.050 |
Why?
|
| California | 3 | 1997 | 161 | 0.050 |
Why?
|
| Mice | 4 | 2022 | 12541 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2010 | 1276 | 0.050 |
Why?
|
| Cell Separation | 1 | 2004 | 205 | 0.050 |
Why?
|
| Hospitals, University | 3 | 1999 | 199 | 0.050 |
Why?
|
| Cell Culture Techniques | 1 | 2004 | 197 | 0.050 |
Why?
|
| Thermodynamics | 1 | 2004 | 329 | 0.050 |
Why?
|
| Canada | 2 | 2007 | 215 | 0.050 |
Why?
|
| Surgical Procedures, Operative | 1 | 2005 | 219 | 0.050 |
Why?
|
| Organ Size | 2 | 2014 | 379 | 0.050 |
Why?
|
| Decision Support Techniques | 1 | 2004 | 186 | 0.050 |
Why?
|
| Cell Line, Transformed | 1 | 2002 | 156 | 0.050 |
Why?
|
| Pain, Postoperative | 1 | 2005 | 277 | 0.050 |
Why?
|
| Temperature | 1 | 2004 | 426 | 0.050 |
Why?
|
| Virus Replication | 2 | 2022 | 326 | 0.050 |
Why?
|
| Adrenal Cortex Hormones | 2 | 1998 | 294 | 0.050 |
Why?
|
| Intracranial Pressure | 1 | 2002 | 90 | 0.050 |
Why?
|
| Antilymphocyte Serum | 5 | 2004 | 69 | 0.050 |
Why?
|
| Regional Blood Flow | 1 | 2002 | 198 | 0.050 |
Why?
|
| Bilirubin | 3 | 1999 | 134 | 0.050 |
Why?
|
| Drug Administration Schedule | 4 | 1998 | 873 | 0.050 |
Why?
|
| Iatrogenic Disease | 1 | 2002 | 72 | 0.050 |
Why?
|
| A549 Cells | 1 | 2022 | 51 | 0.050 |
Why?
|
| Vero Cells | 1 | 2022 | 106 | 0.050 |
Why?
|
| Insulin | 3 | 2018 | 1190 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2002 | 220 | 0.050 |
Why?
|
| Virus Internalization | 1 | 2022 | 45 | 0.040 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2002 | 52 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2010 | 1670 | 0.040 |
Why?
|
| Colorectal Neoplasms | 2 | 2000 | 1069 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2013 | 7230 | 0.040 |
Why?
|
| Cardiotonic Agents | 1 | 2002 | 95 | 0.040 |
Why?
|
| Vancomycin Resistance | 1 | 2001 | 18 | 0.040 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2022 | 90 | 0.040 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2022 | 91 | 0.040 |
Why?
|
| Interferons | 1 | 2022 | 130 | 0.040 |
Why?
|
| Constriction | 1 | 2001 | 27 | 0.040 |
Why?
|
| Biological Availability | 2 | 1998 | 89 | 0.040 |
Why?
|
| Endoribonucleases | 1 | 2022 | 93 | 0.040 |
Why?
|
| Bile | 2 | 2001 | 61 | 0.040 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2001 | 20 | 0.040 |
Why?
|
| Cerebrovascular Circulation | 1 | 2002 | 244 | 0.040 |
Why?
|
| Foreign-Body Migration | 1 | 2001 | 34 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 1981 | 0.040 |
Why?
|
| Respiratory Insufficiency | 2 | 2001 | 205 | 0.040 |
Why?
|
| Positive-Pressure Respiration | 1 | 2001 | 50 | 0.040 |
Why?
|
| Antimetabolites | 1 | 2000 | 24 | 0.040 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2000 | 37 | 0.040 |
Why?
|
| Heart Rate | 1 | 2002 | 519 | 0.040 |
Why?
|
| Respiratory Tract Diseases | 1 | 2000 | 47 | 0.040 |
Why?
|
| Immunotherapy | 2 | 1999 | 766 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2001 | 281 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2021 | 376 | 0.040 |
Why?
|
| Intraoperative Period | 2 | 1997 | 98 | 0.040 |
Why?
|
| Hepatitis, Alcoholic | 1 | 1999 | 18 | 0.040 |
Why?
|
| Computed Tomography Angiography | 1 | 2021 | 166 | 0.040 |
Why?
|
| Fatal Outcome | 2 | 2010 | 304 | 0.040 |
Why?
|
| Cell Transplantation | 1 | 1999 | 48 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2021 | 830 | 0.040 |
Why?
|
| Neurosurgical Procedures | 1 | 2022 | 356 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2000 | 323 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2002 | 929 | 0.040 |
Why?
|
| Emulsions | 1 | 1998 | 19 | 0.040 |
Why?
|
| North America | 1 | 2018 | 199 | 0.040 |
Why?
|
| Nutrition Surveys | 1 | 2019 | 125 | 0.040 |
Why?
|
| Carbamoyl-Phosphate Synthase (Ammonia) | 1 | 1998 | 5 | 0.030 |
Why?
|
| Ornithine Carbamoyltransferase Deficiency Disease | 1 | 1998 | 4 | 0.030 |
Why?
|
| Citrulline | 1 | 1998 | 10 | 0.030 |
Why?
|
| Communication Disorders | 1 | 1998 | 7 | 0.030 |
Why?
|
| Cytokines | 1 | 2022 | 872 | 0.030 |
Why?
|
| Diagnosis, Differential | 3 | 2010 | 1619 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2022 | 705 | 0.030 |
Why?
|
| Multivariate Analysis | 3 | 2010 | 1010 | 0.030 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 1998 | 52 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2001 | 463 | 0.030 |
Why?
|
| Microcephaly | 1 | 1998 | 79 | 0.030 |
Why?
|
| Alcoholism | 1 | 1999 | 191 | 0.030 |
Why?
|
| Vancomycin | 1 | 1998 | 75 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2018 | 235 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2001 | 1471 | 0.030 |
Why?
|
| Coccidioidomycosis | 1 | 1997 | 8 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 1999 | 382 | 0.030 |
Why?
|
| Dosage Forms | 1 | 1996 | 7 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2021 | 1791 | 0.030 |
Why?
|
| Intellectual Disability | 1 | 1998 | 203 | 0.030 |
Why?
|
| Methylprednisolone | 1 | 1996 | 68 | 0.030 |
Why?
|
| Syndrome | 1 | 1997 | 453 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 1996 | 126 | 0.030 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2001 | 514 | 0.030 |
Why?
|
| Oxygen | 1 | 2001 | 788 | 0.030 |
Why?
|
| Situs Inversus | 1 | 1995 | 15 | 0.030 |
Why?
|
| Quality of Life | 3 | 1996 | 1816 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 1133 | 0.030 |
Why?
|
| Pancreatic Function Tests | 1 | 2015 | 7 | 0.030 |
Why?
|
| Somatostatin-Secreting Cells | 1 | 2015 | 7 | 0.030 |
Why?
|
| Logistic Models | 1 | 2018 | 1268 | 0.030 |
Why?
|
| Glucagon-Secreting Cells | 1 | 2015 | 27 | 0.030 |
Why?
|
| Altruism | 1 | 2015 | 34 | 0.030 |
Why?
|
| Administration, Oral | 1 | 1996 | 688 | 0.030 |
Why?
|
| Hepatitis, Viral, Human | 2 | 1999 | 23 | 0.030 |
Why?
|
| Public Opinion | 1 | 2015 | 51 | 0.030 |
Why?
|
| Carbocyanines | 1 | 2014 | 18 | 0.030 |
Why?
|
| Intestine, Small | 1 | 1996 | 310 | 0.030 |
Why?
|
| Succinimides | 1 | 2014 | 12 | 0.030 |
Why?
|
| Streptavidin | 1 | 2014 | 14 | 0.030 |
Why?
|
| Tissue Survival | 1 | 2014 | 13 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2014 | 81 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 344 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2011 | 819 | 0.030 |
Why?
|
| Celiac Plexus | 1 | 1993 | 3 | 0.030 |
Why?
|
| Cell Communication | 1 | 2014 | 221 | 0.030 |
Why?
|
| Nerve Compression Syndromes | 1 | 1993 | 19 | 0.030 |
Why?
|
| Hepatitis B virus | 2 | 2008 | 48 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 380 | 0.020 |
Why?
|
| Leiomyosarcoma | 1 | 1994 | 49 | 0.020 |
Why?
|
| Family | 1 | 1995 | 332 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2013 | 38 | 0.020 |
Why?
|
| Swine | 1 | 2014 | 617 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2011 | 938 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2014 | 433 | 0.020 |
Why?
|
| Hemorrhage | 2 | 2000 | 294 | 0.020 |
Why?
|
| Recurrence | 4 | 1998 | 1218 | 0.020 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2013 | 59 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2013 | 206 | 0.020 |
Why?
|
| Azathioprine | 3 | 1998 | 125 | 0.020 |
Why?
|
| Cholestasis | 1 | 1992 | 44 | 0.020 |
Why?
|
| Abdomen, Acute | 1 | 2012 | 22 | 0.020 |
Why?
|
| T-Lymphocytes | 2 | 1989 | 1316 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2013 | 212 | 0.020 |
Why?
|
| CD3 Complex | 2 | 1989 | 136 | 0.020 |
Why?
|
| Medical Tourism | 1 | 2011 | 6 | 0.020 |
Why?
|
| Immunoassay | 1 | 2012 | 100 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2013 | 180 | 0.020 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2011 | 8 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 1995 | 422 | 0.020 |
Why?
|
| Drainage | 3 | 1998 | 172 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2012 | 191 | 0.020 |
Why?
|
| Advisory Committees | 1 | 2011 | 94 | 0.020 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 1998 | 647 | 0.020 |
Why?
|
| Hepacivirus | 1 | 2012 | 137 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 1998 | 771 | 0.020 |
Why?
|
| Algorithms | 2 | 2014 | 2015 | 0.020 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2010 | 33 | 0.020 |
Why?
|
| Drug Therapy, Combination | 3 | 1998 | 813 | 0.020 |
Why?
|
| Colitis, Ulcerative | 2 | 2013 | 801 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2010 | 74 | 0.020 |
Why?
|
| Brain Death | 1 | 2011 | 88 | 0.020 |
Why?
|
| alpha-Fetoproteins | 1 | 2010 | 46 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 1829 | 0.020 |
Why?
|
| Chemoprevention | 1 | 2010 | 93 | 0.020 |
Why?
|
| Hypertonic Solutions | 1 | 1990 | 17 | 0.020 |
Why?
|
| Abdomen | 1 | 2010 | 127 | 0.020 |
Why?
|
| Solutions | 1 | 1990 | 86 | 0.020 |
Why?
|
| Organ Preservation Solutions | 1 | 1990 | 35 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2011 | 1010 | 0.020 |
Why?
|
| Adenocarcinoma | 2 | 1994 | 1215 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 1807 | 0.020 |
Why?
|
| Kidney Tubular Necrosis, Acute | 2 | 1999 | 9 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 1990 | 182 | 0.020 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 1989 | 12 | 0.020 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1989 | 44 | 0.020 |
Why?
|
| Portoenterostomy, Hepatic | 1 | 1988 | 5 | 0.020 |
Why?
|
| Random Allocation | 1 | 1989 | 327 | 0.020 |
Why?
|
| Rupture | 1 | 2008 | 62 | 0.020 |
Why?
|
| Aspergillosis | 1 | 1988 | 39 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 884 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 901 | 0.020 |
Why?
|
| Methylprednisolone Hemisuccinate | 2 | 1998 | 10 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2008 | 274 | 0.020 |
Why?
|
| Infant, Newborn | 3 | 1998 | 2614 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 553 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 1994 | 1667 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 3490 | 0.020 |
Why?
|
| Rats, Inbred BUF | 3 | 1991 | 4 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2013 | 1323 | 0.020 |
Why?
|
| Los Angeles | 2 | 1996 | 30 | 0.020 |
Why?
|
| Angiography | 1 | 2006 | 209 | 0.020 |
Why?
|
| Crotonates | 1 | 2005 | 12 | 0.010 |
Why?
|
| Toluidines | 1 | 2005 | 18 | 0.010 |
Why?
|
| Combined Modality Therapy | 3 | 1995 | 1773 | 0.010 |
Why?
|
| Hydroxybutyrates | 1 | 2005 | 27 | 0.010 |
Why?
|
| Aniline Compounds | 1 | 2005 | 62 | 0.010 |
Why?
|
| Nitriles | 1 | 2005 | 157 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2004 | 71 | 0.010 |
Why?
|
| Esophageal and Gastric Varices | 2 | 1998 | 36 | 0.010 |
Why?
|
| Urinary Bladder | 2 | 1996 | 263 | 0.010 |
Why?
|
| Lymphocyte Depletion | 1 | 2004 | 101 | 0.010 |
Why?
|
| Small-Area Analysis | 1 | 2003 | 7 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 1989 | 1179 | 0.010 |
Why?
|
| Health Priorities | 1 | 2003 | 28 | 0.010 |
Why?
|
| Geography | 1 | 2003 | 240 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2004 | 458 | 0.010 |
Why?
|
| Neoplasm Staging | 2 | 2000 | 2086 | 0.010 |
Why?
|
| Environmental Microbiology | 1 | 2001 | 22 | 0.010 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 1998 | 246 | 0.010 |
Why?
|
| Portal System | 1 | 2001 | 13 | 0.010 |
Why?
|
| Government Regulation | 1 | 2001 | 50 | 0.010 |
Why?
|
| Focal Nodular Hyperplasia | 1 | 2001 | 10 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2004 | 594 | 0.010 |
Why?
|
| Hamartoma | 1 | 2001 | 33 | 0.010 |
Why?
|
| DNA, Bacterial | 1 | 2001 | 253 | 0.010 |
Why?
|
| Hemangioma | 1 | 2001 | 65 | 0.010 |
Why?
|
| Cytomegalovirus Infections | 1 | 2001 | 155 | 0.010 |
Why?
|
| Rats, Inbred Strains | 2 | 1990 | 311 | 0.010 |
Why?
|
| Lymphotoxin-alpha | 2 | 1990 | 43 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2001 | 218 | 0.010 |
Why?
|
| Alanine Transaminase | 2 | 1990 | 73 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 2 | 1990 | 75 | 0.010 |
Why?
|
| Cysts | 1 | 2001 | 104 | 0.010 |
Why?
|
| Fibrosis | 1 | 2001 | 246 | 0.010 |
Why?
|
| Risk | 1 | 2001 | 668 | 0.010 |
Why?
|
| Feces | 1 | 2001 | 360 | 0.010 |
Why?
|
| Cell Division | 1 | 2001 | 705 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 2001 | 257 | 0.010 |
Why?
|
| Radiography, Thoracic | 1 | 2001 | 334 | 0.010 |
Why?
|
| Adenoma | 1 | 2001 | 260 | 0.010 |
Why?
|
| Plasmapheresis | 1 | 1998 | 27 | 0.010 |
Why?
|
| Pregnancy | 2 | 2001 | 3240 | 0.010 |
Why?
|
| Pneumonia | 1 | 2000 | 197 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1998 | 72 | 0.010 |
Why?
|
| Gallbladder Diseases | 1 | 1998 | 21 | 0.010 |
Why?
|
| Aminosalicylic Acids | 1 | 1998 | 41 | 0.010 |
Why?
|
| Pregnancy Complications | 1 | 2001 | 356 | 0.010 |
Why?
|
| Radiology, Interventional | 1 | 1998 | 66 | 0.010 |
Why?
|
| Complement C3 | 1 | 1997 | 58 | 0.010 |
Why?
|
| Urinary Retention | 1 | 1997 | 46 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2000 | 290 | 0.010 |
Why?
|
| Renal Insufficiency | 1 | 1998 | 99 | 0.010 |
Why?
|
| Capillaries | 1 | 1997 | 86 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1997 | 66 | 0.010 |
Why?
|
| Fluconazole | 1 | 1997 | 11 | 0.010 |
Why?
|
| Fibrin | 1 | 1997 | 87 | 0.010 |
Why?
|
| Amphotericin B | 1 | 1997 | 37 | 0.010 |
Why?
|
| Bacteremia | 1 | 1998 | 108 | 0.010 |
Why?
|
| Kidney Glomerulus | 1 | 1997 | 122 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 1996 | 141 | 0.010 |
Why?
|
| Treatment Failure | 1 | 1997 | 297 | 0.010 |
Why?
|
| Neutrophils | 1 | 1997 | 332 | 0.010 |
Why?
|
| Bone Diseases | 1 | 1995 | 54 | 0.010 |
Why?
|
| Diabetic Nephropathies | 1 | 1995 | 90 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1997 | 481 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 1996 | 238 | 0.010 |
Why?
|
| Safety | 1 | 1995 | 147 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 1997 | 369 | 0.010 |
Why?
|
| Extremities | 1 | 1995 | 179 | 0.010 |
Why?
|
| Immunization, Passive | 1 | 1994 | 75 | 0.010 |
Why?
|
| Emergencies | 1 | 1995 | 124 | 0.010 |
Why?
|
| Postoperative Care | 1 | 1995 | 239 | 0.010 |
Why?
|
| Ischemia | 1 | 1995 | 257 | 0.010 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 1993 | 40 | 0.010 |
Why?
|
| Choledochostomy | 1 | 1992 | 8 | 0.010 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 1992 | 14 | 0.010 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 1992 | 26 | 0.010 |
Why?
|
| Therapeutic Irrigation | 1 | 1992 | 66 | 0.010 |
Why?
|
| Dilatation | 1 | 1992 | 48 | 0.010 |
Why?
|
| Immune Sera | 1 | 1991 | 53 | 0.010 |
Why?
|
| Adenoma, Bile Duct | 1 | 1990 | 4 | 0.010 |
Why?
|
| Rats, Inbred BN | 1 | 1990 | 37 | 0.010 |
Why?
|
| Immunologic Techniques | 1 | 1990 | 27 | 0.010 |
Why?
|
| Transplantation, Isogeneic | 1 | 1990 | 40 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1990 | 228 | 0.010 |
Why?
|
| Raffinose | 1 | 1990 | 24 | 0.010 |
Why?
|
| Allopurinol | 1 | 1990 | 78 | 0.000 |
Why?
|
| Glutathione | 1 | 1990 | 107 | 0.000 |
Why?
|
| Recombinant Proteins | 1 | 1991 | 1034 | 0.000 |
Why?
|
| Cardiovascular Diseases | 1 | 1995 | 777 | 0.000 |
Why?
|
| Evaluation Studies as Topic | 1 | 1989 | 271 | 0.000 |
Why?
|
| Analysis of Variance | 1 | 1990 | 909 | 0.000 |
Why?
|
| Occupations | 1 | 1988 | 25 | 0.000 |
Why?
|
| Adenosine | 1 | 1990 | 278 | 0.000 |
Why?
|
| Activities of Daily Living | 1 | 1988 | 216 | 0.000 |
Why?
|
| Patient Acceptance of Health Care | 1 | 1988 | 296 | 0.000 |
Why?
|